A biopsy is a medical test to remove the piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. While, in cancer biopsy, a tissue or cells of the affected patient is taken to discover the presence, cause, or extent of cancer. Thus, with the rising burden of cancer across the globe, the use of cancer biopsy or cancer biopsies also increasing with a rapid pace.
Market Dynamics:
Increasing prevalence of oncology disorders, growing geriatric population, advent of liquid biopsy or increasing adoption of liquid biopsies, increasing awareness among people about genetic testing and inherited oncology diseases, and ongoing developments in biopsy techniques are major factors expected to augment the growth of the global cancer biopsy market.
For instance, in May 2022, Delfi Diagnostics, a developer of a new class of high-performance and affordable liquid biopsy tests for early cancer detection, presented multiple applications for its next-generation liquid biopsy platform. Delfi presented a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection.
Key features of the study:
- This report provides in-depth analysis of the global cancer biopsy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global cancer biopsy market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include QIAGEN, Illumina, Inc., Angle PLC, Myriad Genetics, COUNSYL, Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, F. Hoffmann-La Roche Ltd., Epigenomics AG, BD (Becton, Dickinson and Company), and Helio Health (Laboratory for Advanced Medicine), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global cancer biopsy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biopsy market.
Detailed Segmentation:
- Global Cancer Biopsy Market , By Product:
- Instruments
- Kits and Consumables
- Services
- Global Cancer Biopsy Market , By Biopsy Type:
- Tissue Biopsy
- Needle Biopsy
- Fine Needle Aspiration (FNA)
- Core Needle Biopsy (CNB)
- Liquid Biopsy
- Others
- Global Cancer Biopsy Market, By Application:
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
- Global Cancer Biopsy Market , By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles:
- QIAGEN
- Illumina, Inc.
- Angle PLC
- Myriad Genetics
- COUNSYL, Inc.
- Hologic, Inc.
- Biocept, Inc.
- Thermo Fisher Scientific, Inc.
- Danaher
- Hoffmann-La Roche Ltd.
- Epigenomics AG
- BD (Becton, Dickinson and Company)
- Helio Health (Laboratory for Advanced Medicine)
